Illuminating the Nervous System with Transvascular Precision-Guided Technology
Autonomix is developing a new minimally invasive nerve-sensing, ablation and verification system with sensing capability up to 3,000* times more sensitive than current technologies available that could transform the field of electrophysiology with a simple and routine transvascular procedure.
First-In-Class System
Autonomix’s first-in-class system, with its proprietary precision guidance sense, treat and verify technology, is able to identify and target specific nerves throughout the body that are implicated in various diseases, then kill responsible nerves through its radio frequency (RF) ablation technology, and finally verify nerve signaling has stopped.
Platform Technology
Autonomix is a platform technology that has the potential to revolutionize therapeutic electrophysiology and address a number of disease categories from chronic pain management to hypertension and cardiology.
Discover the Power of Autonomix’s Nerve Sensing Catheter Technology
Autonomix’s state-of-the-art custom antennae array is capable of detecting electrical nerve signaling with up to 3,000* times greater sensitivity than currently available technology, providing real time data that allows physicians to identify and target overactive nerves for ablation.
3000x*
More Sensitive with Greater Ability to Detect & Differentiate Neural Signals
120+
Patents Issued or Pending
Platform
Platform Technology with Unlimited Application Opportunities Across a Wide Disease Spectrum
Who We Help.
Advancing Innovation in Nervous System Technologies.
Autonomix’s singular purpose is to transform patient outcomes with precision technology that can revolutionize how diseases involving the peripheral nervous system are diagnosed and treated.
Initially, efforts are focused on helping pancreatic cancer patients who are suffering from pain that is not relieved by currently available methods. These patients suffer excruciating pain, and current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects. The goal is to provide pain relief and a better quality of life for these patients by giving them safer, more effective relief.
Once the effectiveness is demonstrated, the breadth of the technology can be expanded to target additional treatment options and help even more patients.
Clinical Evidence
Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
Clinically Meaningful Reduction of Pain on the VAS Pain Scale
Responders Required Zero Opioid Use at 7 Days**
No Procedural-Related Significant Adverse Events or Unexpected Complications
Physician and Lead-In Patient Interviews from First-In-Human Trial
The Autonomix Opportunity
Proof-of-Concept in Lead Pancreatic Cancer Pain Indication Opens Up a $100 Billion Market Opportunity Across Multiple Indications
Chronic Pain Management
- Pancreatic Cancer Pain
- Cancer Pain
- Chronic Pain
- Neuropathic Pain
Cardiovascular Conditions
- Hypertension (High Blood Pressure)
- Refractory Angina
- Atrial Fibrillation (AFib)
Pulmonary Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Hypertension
- Chronic Cough
* Data on File
** 36% of responders were on opioid at screening visit